肝移植前后伏立康唑给药与治疗药物监测
单中心回顾性队列研究评估晚期肝硬化患者肝移植前后伏立康唑给药与TDM,移植前队列76例124个浓度,移植后36例71个浓度,目标谷浓度1-4 mcg/mL。移植前剂量低于2 mg/kg/剂更可能达治疗浓度,移植后仅23/71浓度在治疗范围内;建议移植前经验性剂量不超过2 mg/kg/剂,移植后可恢复标准剂量,TDM必不可少。
要点
- 移植前经验性伏立康唑剂量不应超过2 mg/kg/剂,以减少蓄积和毒性风险
- 移植后仅23/71浓度达标(平均剂量2.8 mg/kg/剂),可考虑恢复标准剂量
- 移植前后药代动力学变异大,TDM对安全有效管理至关重要
核心结论
- 晚期肝硬化等待肝移植评估的患者,伏立康唑经验性初始剂量不应超过2 mg/kg/剂,以降低药物蓄积和潜在毒性风险。
- 肝移植后患者可合理考虑恢复标准剂量,且因药代动力学变异大,TDM对有效安全用药至关重要。
研究设计与样本
- 单中心回顾性队列研究,评估晚期肝硬化患者在紧急肝移植评估和/或手术期间接受伏立康唑的给药与TDM。
- 移植前队列76例患者124个浓度,移植后队列36例患者71个浓度;纳入标准为移植前用药至少7天或移植后至少5天采集谷浓度。
主要发现
- 移植前组肝酶异常更明显,MELD评分中位数35(IQR 29.5-40)。
- 移植前剂量低于2 mg/kg/剂更可能与伏立康唑治疗浓度相关。
- 41例出现超治疗浓度(平均剂量2.4 mg/kg/剂),其中5例需中断治疗。
- 移植后71个浓度中仅23个在治疗范围内(平均剂量2.8 mg/kg/剂)。
关键数值与推荐
- 目标治疗谷浓度范围定义为1-4 mcg/mL。
- 移植前经验性剂量建议不超过2 mg/kg/剂;移植后可考虑恢复标准剂量。
临床怎么用
- 对晚期肝硬化等待肝移植评估的患者,伏立康唑初始经验性剂量应控制在2 mg/kg/剂以下。
- 肝移植后可根据标准剂量给药,但需密切进行TDM以确保浓度在1-4 mcg/mL目标范围内。
局限性
- 单中心回顾性设计可能限制结果的普遍性。
- 样本量有限(移植前76例、移植后36例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Voriconazole is a triazole antifungal, primarily metabolized by the liver, and poses a dosing challenge in patients with liver impairment. Although the manufacturer recommends a maintenance dose reduction for mild-to-moderate hepatic dysfunction, no standardized recommendations exist for severe liver impairment. Prior evidence suggests a need for significant dose reduction in the setting of severe liver failure; however, there is limited data on empirical dosing in patients undergoing orthotopic liver transplant (OLT) evaluation and surgery. METHODS: This is a single-center, retrospective cohort study assessing voriconazole dosing and therapeutic drug monitoring (TDM) in patients with advanced cirrhosis who received voriconazole during urgent OLT evaluation and/or surgery. Patients were included if voriconazole trough concentrations were collected at least 7 days after therapy initiation pre-OLT or at least 5 days post-OLT. The target therapeutic range was defined as 1-4 mcg/mL. The primary outcome was the distribution of voriconazole trough concentrations in the pre- and post-transplant cohorts. RESULTS: The pre-OLT cohort comprised 76 patients with 124 concentrations, and the post-OLT cohort comprised 36 patients with 71 concentrations. As anticipated, the pre-OLT group exhibited more abnormal liver enzymes and a high median Model for End-Stage Liver Disease (MELD) score of 35 (Interquartile Range (IQR) 29.5-40). In the pre-OLT setting, doses less than 2 mg/kg/dose were more likely associated with therapeutic voriconazole concentrations. Supratherapeutic concentrations were observed in 41 patients (average dose of 2.4 mg/kg/dose), of which five patients required therapy interruption. In the post-OLT group, only 23 of 71 concentrations fell within the therapeutic range, with an average dose of 2.8 mg/kg/dose. CONCLUSION: We found that empiric voriconazole dosing in patients with advanced cirrhosis undergoing OLT evaluation should not exceed 2 mg/kg/dose initially to mitigate the risk of drug accumulation and potential toxicity. In post-OLT patients, it is reasonable to consider reverting to standard manufacturer-recommended dosing. Given the pharmacokinetic variability observed, TDM is essential for effective and safe management in this high-risk patient population.
引用
- Hoffmann WJ, Tsai S, Succar L, et al. Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation. Pharmacotherapy. 2026. PMID: 42272052. doi:10.1002/phar.70176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。